A tyrosine kinase inhibitor that potently inhibits Bcr/Abl tyrosine kinase and is effective in the treatment of certain leukemias; ~20-fold more potent than imatinib in inhibiting Bcr/Abl (e.g., IC50 = 15 versus 280 nM, respectively).